Understanding LCHAD Deficiency: Basics & Biology
At a Glance
LCHAD deficiency is a rare genetic disorder where a mutation in the HADHA gene prevents the body from breaking down long-chain fats into energy. This causes dangerous low blood sugar and toxic fat buildup during fasting. It is typically detected by newborn screening and managed with a strict diet.
Receiving a diagnosis of LCHAD deficiency (Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase deficiency) can feel overwhelming, especially if it arrived through a routine newborn screening or a sudden medical emergency. It is important to know that while this is a serious condition, understanding the biology behind it is the first step in protecting your child’s health. With early detection and careful management, the focus shifts from a “scary unknown” to a manageable daily routine [1].
The Energy Factory: Why Fat Matters
To understand LCHAD, it helps to think of the body’s energy system. Most of the time, our bodies run on sugar (glucose). However, when we go a long time without eating (fasting) or when we are sick, the body switches to burning fat for fuel.
In children with LCHAD deficiency, the body cannot finish the process of breaking down long-chain fats—the type of fat found in most oils and many foods [2]. This happens because of a specific “hiccup” in the mitochondria, which are the power plants of every cell in the body [3].
The Biological Mechanism: The MTP Complex
LCHAD is part of a larger team of enzymes called the Mitochondrial Trifunctional Protein (MTP) complex [2]. This complex is responsible for the final steps of breaking down long-chain fats into energy.
- The Gene: The instructions for building the part of this team that handles LCHAD are found on the HADHA gene [3].
- The Subunit: Specifically, the HADHA gene creates the alpha subunit of the MTP complex [2].
When there is a mutation in the HADHA gene, the LCHAD enzyme doesn’t work correctly. This leads to two major problems:
- Energy Shortage: The body cannot produce enough energy from fat, leading to dangerously low blood sugar (hypoglycemia) during periods of fasting or illness [4].
- Toxic Buildup: Instead of being fully broken down, the fats stop halfway through the process. These partially broken-down fats, called long-chain 3-hydroxy fatty acids, begin to build up in the blood and organs [5].
How Buildup Affects the Body
These “halfway-broken” fats are toxic to the body’s tissues. If they accumulate, they can cause damage in several areas:
- The Heart: The heart is an organ that relies heavily on fat for energy. A buildup of toxic intermediates can cause cardiomyopathy (weakening of the heart muscle) [6].
- The Liver: Toxic fats can lead to liver enlargement or dysfunction, a process sometimes called lipoapoptosis (cell death caused by fat buildup) [5].
- The Muscles: During a crisis, muscle tissue can break down (rhabdomyolysis), releasing a protein called myoglobin that can be hard on the kidneys [4].
- The Eyes: Over time, the buildup may affect the retina, leading to retinopathy (vision changes), which is why regular eye exams are vital [7].
How LCHAD is Diagnosed
Most babies are now identified through Newborn Screening. This is done using a technology called tandem mass spectrometry (MS/MS), which scans the blood for specific markers [8].
- Markers: Doctors look for high levels of 3-hydroxy-acylcarnitines, specifically markers labeled as C16-OH, C18-OH, and C18:1-OH [8][9].
- Confirmation: Because screening is just a “first look,” doctors must confirm the diagnosis using molecular genetic testing to find the specific mutation in the HADHA gene [1][10].
A Note on Pregnancy
Interestingly, LCHAD deficiency in a baby can sometimes cause health issues for the mother during pregnancy. This is because the toxic fats produced by the fetus can enter the mother’s bloodstream [5]. If the mother experienced HELLP syndrome (high blood pressure and liver issues) or Acute Fatty Liver of Pregnancy (AFLP), it may have been an early sign of the baby’s LCHAD deficiency [11][3].
While your child will always be metabolically fragile—meaning they require a strict diet and cannot fast for long periods—early diagnosis is a life-saving tool that allows your medical team to prevent these crises before they begin [1][12].
Common questions in this guide
What causes LCHAD deficiency?
How is LCHAD deficiency diagnosed in babies?
What happens if a child with LCHAD goes too long without eating?
Can a baby's LCHAD deficiency affect the mother during pregnancy?
Why are regular eye exams important for a child with LCHAD?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Has my child's diagnosis been confirmed with genetic testing of the HADHA and HADHB genes?
- 2.What are my child's specific levels of 3-hydroxy-acylcarnitines, and how do they compare to the newborn screening threshold?
- 3.Based on my child's labs, should we be looking for early signs of heart (cardiomyopathy) or eye (retinopathy) issues?
- 4.Can you help me create an 'Emergency Protocol' letter to give to the ER in case of a metabolic crisis?
- 5.How does my child's diagnosis impact the risk of pregnancy complications for our family in the future?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (12)
- 1
Fatal pitfalls in newborn screening for mitochondrial trifunctional protein (MTP)/long-chain 3-Hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency.
Lotz-Havla AS, Röschinger W, Schiergens K, et al.
Orphanet journal of rare diseases 2018; (13(1)):122 doi:10.1186/s13023-018-0875-6.
PMID: 30029694 - 2
Deep geno- and phenotyping in two consanguineous families with CMT2 reveals HADHA as an unusual disease-causing gene and an intronic variant in GDAP1 as an unusual mutation.
Khani M, Taheri H, Shamshiri H, et al.
Journal of neurology 2021; (268(2)):640-650 doi:10.1007/s00415-020-10171-4.
PMID: 32897397 - 3
Mitochondrial trifunctional protein deficiency due to HADHB gene mutation in a Chinese family.
Fu X, Zheng F, Zhang Y, et al.
Molecular genetics and metabolism reports 2015; (5()):80-84 doi:10.1016/j.ymgmr.2015.10.015.
PMID: 28649548 - 4
An Autopsy Analysis of a Patient With Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency Caused by Compound Heterozygous HADHA Gene Mutations.
Zhang Q, Yao N, Liu Z, et al.
The American journal of forensic medicine and pathology 2023; (44(4)):336-339 doi:10.1097/PAF.0000000000000872.
PMID: 37549033 - 5
Role of 3-Hydroxy Fatty Acid-Induced Hepatic Lipotoxicity in Acute Fatty Liver of Pregnancy.
Natarajan SK, Ibdah JA
International journal of molecular sciences 2018; (19(1)) doi:10.3390/ijms19010322.
PMID: 29361796 - 6
Deregulation of mitochondrial functions provoked by long-chain fatty acid accumulating in long-chain 3-hydroxyacyl-CoA dehydrogenase and mitochondrial permeability transition deficiencies in rat heart--mitochondrial permeability transition pore opening as a potential contributing pathomechanism of cardiac alterations in these disorders.
Cecatto C, Hickmann FH, Rodrigues MD, et al.
The FEBS journal 2015; (282(24)):4714-26 doi:10.1111/febs.13526.
PMID: 26408230 - 7
Retained visual function in a subset of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD).
Dulz S, Atiskova Y, Engel P, et al.
Ophthalmic genetics 2021; (42(1)):23-27 doi:10.1080/13816810.2020.1836658.
PMID: 33107778 - 8
[Newborn screening in France: news and perspectives].
Gernez E, Roland E, Dhaenens CM, et al.
Annales de biologie clinique 2024; (82(1)):24-31 doi:10.1684/abc.2024.1869.
PMID: 38638016 - 9
Neurological outcome in long-chain hydroxy fatty acid oxidation disorders.
Mütze U, Ottenberger A, Gleich F, et al.
Annals of clinical and translational neurology 2024; (11(4)):883-898 doi:10.1002/acn3.52002.
PMID: 38263760 - 10
Outcomes and genotype correlations in patients with mitochondrial trifunctional protein or isolated long chain 3-hydroxyacyl-CoA dehydrogenase deficiency enrolled in the IBEM-IS database.
Lim CC, Vockley J, Ujah O, et al.
Molecular genetics and metabolism reports 2022; (32()):100884 doi:10.1016/j.ymgmr.2022.100884.
PMID: 35677112 - 11
Acute Fatty Liver of Pregnancy and Fetal Fatty Acid Oxidation Disorders: A Systematic Review.
Varotsis D, Araji S, Horgan R, et al.
O&G open 2026; (3(1)):e148 doi:10.1097/og9.0000000000000148.
PMID: 41727930 - 12
A Focus on the Role of Dietary Treatment in the Prevention of Retinal Dysfunction in Patients with Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency: A Systematic Review.
Maines E, Gugelmo G, Vitturi N, et al.
Children (Basel, Switzerland) 2025; (12(3)) doi:10.3390/children12030374.
PMID: 40150656
This page provides educational information about LCHAD deficiency biology and diagnosis. It does not replace professional medical advice. Always consult your pediatric metabolic specialist regarding your child's care and emergency protocols.
Get notified when new evidence is published on Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.